*Non-Small-Cell Lung Cancer *NSCLC
Conditions
Interventions
Drug: Lorlatinib
ALK-positive NSCL treatment
Other Name: PF-06463922
Sponsors
Kawai Norisuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1 - Any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study with no ongoing NCI CTCAE Grade >=3 or intolerable Grade 2 AEs considered to be related to lorlatinib treatment. 2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1 - Female participants who are pregnant or breastfeeding. 2- Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measures : 1.Number of participants with adverse events leading to permanent discontinuation of study intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| not aplicable | — |
Countries
China, France, India, Japan, Singapore, Spain, Taiwan, United States
Contacts
Public ContactClinical Trials Information Desk
Pfizer R&D Japan G.K.
Outcome results
None listed